Pulmonx LUNG

NASDAQ LUNG

$2.87 +0.07 (+2.50%)

As of: Nov 10, 2026 · 10:20 AM EST

Pulmonx (LUNG) stock price is $2.87, up 2.50% on the day, as of Nov 10, 2026. It has a market cap of $116.67Mn, and is classified in the Medical Devices industry (Healthcare sector).

Key Stats

Market Cap116.67 Mn

P/E–

FCF (Yr)–

ROA (Yr)–

EV to EBIT–

Net Income (Yr)–

Enterprise Value-202.56 Mn

Add ratio to table…

About

Pulmonx is a commercial stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema a form of chronic obstructive pulmonary disease. The company’s solution includes the Zephyr Valve the Chartis System and the LungTraX Platform. It operates in the medical device industry focusing on pulmonary therapies. Pulmonx generates revenue primarily from the sale of Zephyr Valves and associated delivery catheters. Additional…

Investment Thesis

▲ Bull case

The company is demonstrating early but meaningful progress in stabilizing its U.S. sales force, which is foundational to reaccelerating revenue growth. Management reported that sales turnover has stabilized over the last six months after earlier volatility in 2025, and they expect turnover to align with industry standards moving forward. This stabilization is attributed to increased leadership transparency and a streamlined focus on high-impact activities, which is reducing operational friction and allowing new hires to ramp up more effectively. With all U.S. field sales roles now substantially filled and top talent in place across sales leadership, the company is building a more consistent execution model. The near-to-far strategy—centered on setting up efficient valve programs, engaging COPD-aligned clinicians, securing administrative support, and targeting geographies with established treating centers—is already yielding positive early feedback from both the field force and customers. As newer reps become productive over the course of the year, the company expects U.S. sales performance to improve sequentially, with growth reacceleration anticipated in the back half of 2026. This turnaround in sales force productivity, combined with a refocused commercial approach, positions Pulmonx to capture a larger share of its addressable market in the U.S., where underlying demand for Zephyr Valves remains strong despite recent execution challenges.
The international business, excluding China, is showing robust underlying growth that is being masked by temporary China-related headwinds, creating a meaningful inflection point for reacceleration. Excluding China, international revenue grew 22% year-over-year in Q1 FY26 and 9% on a constant currency basis, reflecting sustained strength in direct markets across Europe and other regions. Management emphasized that this underlying business has delivered double-digit growth for the past couple of years and expects this trend to continue. The current decline in reported international revenue is entirely due to the absence of sales to its China distributor while awaiting registration certificate renewal, which is expected in the second half of 2026. Importantly, China represents less than 5% of total sales, so its impact is disproportionate to the perceived weakness. Once the registration is renewed and sales resume—albeit gradually—the company will begin lapping the tough year-over-year comparisons from the first half of 2025, when large China orders were recorded. This anniversary effect will allow the underlying strength of the direct international business to shine through, driving a return to positive year-over-year growth in the international segment in the back half of 2026. With no structural issues identified in core international markets and continued momentum in direct sales, the international segment is poised to become a reliable growth engine as China-related drag diminishes.
The AeriSeal program represents a significant, underappreciated long-term catalyst that could expand the company’s total addressable market by approximately 20% globally, with progress advancing faster than market expectations. Management expressed high confidence in completing enrollment of the CONVERT II pivotal trial by 2027, citing improved pace since bringing on new leadership in clinical affairs. Unlike the Zephyr Valves, which treat severe emphysema, AeriSeal targets a broader COPD patient population, including those with heterogeneous emphysema who are not currently eligible for valve therapy. This expansion of the addressable market is not merely incremental—it opens access to millions of additional patients who suffer from advanced COPD but lack effective minimally invasive treatment options. The company views AeriSeal as both a future revenue driver and a market expander for Zephyr Valves, as success in this program could increase physician and health system awareness of Pulmonx’s broader COPD solutions. While the near-term focus remains on execution and profitability, the clinical progress in AeriSeal is de-risking a major pipeline asset that could transform the company’s growth trajectory beyond 2026. Investors may be underestimating the probability of success and the timing of potential approval, especially given the encouraging enrollment trends and the unmet medical need in the broader COPD space.
The company has successfully aligned its cost structure with strategic priorities, creating operating leverage that could accelerate profitability even before top-line growth fully materializes. Through a broad cost reduction initiative executed in Q1 FY26, Pulmonx lowered its ongoing operating expenses by over 10% and is on track to deliver full-year 2026 operating expenses between $113 million and $115 million, including approximately $19 million in noncash stock-based compensation. Excluding one-time restructuring charges and stock-based compensation, Q1 operating expenses decreased 8% year-over-year, reflecting disciplined spending on SG&A and R&D while maintaining investments in key growth drivers like U.S. sales ramp and AeriSeal development. Gross margin improved to 78% in Q1 FY26 from 73% in the prior year period, driven by a lower mix of lower-margin distributor sales internationally, and is expected to trend around 75% for the full year. With cash reserves of $61.6 million at quarter-end and a newly secured $60 million credit facility (with a 5-year interest-only structure and access to an additional $20 million undrawn upon revenue milestones), the company expects to burn only ~$23 million in cash for the full year—down from $32 million in 2025. This improved cash burn profile, combined with reducing operating leverage, means that even modest sequential revenue improvements in the back half of the year could translate into meaningful progress toward breakeven or adjusted profitability sooner than anticipated. The market may be overlooking how quickly operating efficiency gains can accrue to the bottom line as the sales force ramps and cost discipline holds.

The company is demonstrating early but meaningful progress in stabilizing its U.S. sales force, which is foundational to reaccelerating revenue growth. Management reported that sales turnover has stabilized over the last six months after earlier volatility in 2025, and they expect turnover to align with industry standards moving forward. This stabilization is attributed to increased leadership transparency and a streamlined focus on high-impact activities, which is reducing operational friction and allowing new hires to ramp up more effectively. With all U.S. field sales roles now substantially filled and top talent in place across sales leadership, the company is building a more consistent execution model. The near-to-far strategy—centered on setting up efficient valve programs, engaging COPD-aligned clinicians, securing administrative support, and targeting geographies with established treating centers—is already yielding positive early feedback from both the field force and customers. As newer reps become productive over the course of the year, the company expects U.S. sales performance to improve sequentially, with growth reacceleration anticipated in the back half of 2026. This turnaround in sales force productivity, combined with a refocused commercial approach, positions Pulmonx to capture a larger share of its addressable market in the U.S., where underlying demand for Zephyr Valves remains strong despite recent execution challenges.
The international business, excluding China, is showing robust underlying growth that is being masked by temporary China-related headwinds, creating a meaningful inflection point for reacceleration. Excluding China, international revenue grew 22% year-over-year in Q1 FY26 and 9% on a constant currency basis, reflecting sustained strength in direct markets across Europe and other regions. Management emphasized that this underlying business has delivered double-digit growth for the past couple of years and expects this trend to continue. The current decline in reported international revenue is entirely due to the absence of sales to its China distributor while awaiting registration certificate renewal, which is expected in the second half of 2026. Importantly, China represents less than 5% of total sales, so its impact is disproportionate to the perceived weakness. Once the registration is renewed and sales resume—albeit gradually—the company will begin lapping the tough year-over-year comparisons from the first half of 2025, when large China orders were recorded. This anniversary effect will allow the underlying strength of the direct international business to shine through, driving a return to positive year-over-year growth in the international segment in the back half of 2026. With no structural issues identified in core international markets and continued momentum in direct sales, the international segment is poised to become a reliable growth engine as China-related drag diminishes.
The AeriSeal program represents a significant, underappreciated long-term catalyst that could expand the company’s total addressable market by approximately 20% globally, with progress advancing faster than market expectations. Management expressed high confidence in completing enrollment of the CONVERT II pivotal trial by 2027, citing improved pace since bringing on new leadership in clinical affairs. Unlike the Zephyr Valves, which treat severe emphysema, AeriSeal targets a broader COPD patient population, including those with heterogeneous emphysema who are not currently eligible for valve therapy. This expansion of the addressable market is not merely incremental—it opens access to millions of additional patients who suffer from advanced COPD but lack effective minimally invasive treatment options. The company views AeriSeal as both a future revenue driver and a market expander for Zephyr Valves, as success in this program could increase physician and health system awareness of Pulmonx’s broader COPD solutions. While the near-term focus remains on execution and profitability, the clinical progress in AeriSeal is de-risking a major pipeline asset that could transform the company’s growth trajectory beyond 2026. Investors may be underestimating the probability of success and the timing of potential approval, especially given the encouraging enrollment trends and the unmet medical need in the broader COPD space.
The company has successfully aligned its cost structure with strategic priorities, creating operating leverage that could accelerate profitability even before top-line growth fully materializes. Through a broad cost reduction initiative executed in Q1 FY26, Pulmonx lowered its ongoing operating expenses by over 10% and is on track to deliver full-year 2026 operating expenses between $113 million and $115 million, including approximately $19 million in noncash stock-based compensation. Excluding one-time restructuring charges and stock-based compensation, Q1 operating expenses decreased 8% year-over-year, reflecting disciplined spending on SG&A and R&D while maintaining investments in key growth drivers like U.S. sales ramp and AeriSeal development. Gross margin improved to 78% in Q1 FY26 from 73% in the prior year period, driven by a lower mix of lower-margin distributor sales internationally, and is expected to trend around 75% for the full year. With cash reserves of $61.6 million at quarter-end and a newly secured $60 million credit facility (with a 5-year interest-only structure and access to an additional $20 million undrawn upon revenue milestones), the company expects to burn only ~$23 million in cash for the full year—down from $32 million in 2025. This improved cash burn profile, combined with reducing operating leverage, means that even modest sequential revenue improvements in the back half of the year could translate into meaningful progress toward breakeven or adjusted profitability sooner than anticipated. The market may be overlooking how quickly operating efficiency gains can accrue to the bottom line as the sales force ramps and cost discipline holds.

▼ Bear case

The company’s U.S. sales recovery remains overly dependent on the ramp-up of newly hired sales representatives, introducing execution risk if productivity gains do not materialize on management’s anticipated timeline. While Pulmonx has substantially filled its U.S. field sales roles and leadership positions, it acknowledges that new hires typically take 6 to 9 months to reach full productivity, implying that meaningful contribution from these reps may not begin until mid-to-late 2026. The company’s guidance for sequential improvement and back-half growth acceleration hinges on this ramp, yet it offered no concrete leading indicators—such as quota attainment, activity levels, or conversion rates—to validate that the sales force is progressing beyond mere headcount completion. Historical patterns show that even with full hiring, sales force effectiveness can lag due to insufficient training, unclear territory alignment, or weak adoption of the new near-to-far strategy. Management cited improved culture and stabilized turnover but did not address whether reps are consistently executing the prioritized activities—like setting up high-quality valve programs or securing administrative support—or if they are reverting to diffuse, low-yield efforts. Without evidence of changing behavior or early productivity metrics, the assumption that growth will reaccelerate in the second half relies on hope rather than proven operational readiness, leaving the U.S. recovery vulnerable to delays if reps fail to ramp as expected.
The international growth ex-China, while appearing strong, may be overstated due to reliance on low-base growth and temporary tailwinds that are not sustainable or scalable. Although Pulmonx reported 22% year-over-year international growth excluding China in Q1 FY26, this figure comes off a depressed base from the prior year, particularly in certain direct markets where performance may have been artificially suppressed by one-time factors such as delayed orders, temporary purchasing patterns, or non-recurring tenders. The company did not provide a breakdown of which specific countries or regions are driving this growth, nor did it clarify whether the increase is broad-based or concentrated in a few smaller markets. Furthermore, the 9% constant currency growth suggests that foreign exchange is flattering the reported number, implying that underlying volume growth is even weaker than the headline figure implies. There was no discussion of market share gains, new account acquisition rates outside of the U.S., or repeat purchasing behavior—key indicators of durable demand. Without evidence that this growth is driven by expanding penetration, improved reimbursement, or structural adoption of Zephyr Valves in core European markets, the ex-China performance could reflect a short-term bounce rather than a sustainable trend. If this growth proves transient, the international segment may not deliver the expected inflection in the back half of the year, especially once China-related comparisons lap and the true underlying momentum is tested.
The AeriSeal program, while positioned as a long-term TAM expander, faces significant clinical, regulatory, and commercialization risks that are being underplayed in management’s optimistic timeline for trial completion and potential approval. Management expressed confidence in completing enrollment of the CONVERT II pivotal trial by 2027, yet provided no interim milestones, data monitoring plans, or clarification on the trial’s primary endpoint, statistical power, or patient population specifics—raising questions about whether the timeline is realistic given historical delays in pulmonary device trials. Even if enrollment completes on schedule, the path to regulatory approval remains uncertain, as AeriSeal is a polymer-based sealant delivered via bronchoscopy, a delivery method with mixed historical success in lung applications and potential concerns about long-term safety, durability, and potential for adverse events like migration or inflammation. The company did not address how it plans to differentiate AeriSeal from prior failed sealant technologies or what reimbursement pathway it expects, particularly given that current COPD treatments face stringent cost-effectiveness scrutiny. Furthermore, there was no discussion of commercial readiness—such as training requirements, procedure reimbursement codes, or hospital adoption barriers—suggesting that the assumption of AeriSeal as a near-to-medium term revenue driver may be premature. If clinical outcomes are equivocal or approval is delayed beyond 2027, the expected 20% TAM expansion may not materialize, leaving the company overly reliant on the niche Zephyr Valves market for growth.
The company’s financial leverage and cash runway improvements, while beneficial, may be insufficient to withstand a prolonged delay in revenue recovery, especially if cost-cutting begins to impair growth investments. Although Pulmonx has reduced operating expenses by over 10% through restructuring and secured a $60 million credit facility with additional undrawn capacity, its cash burn guidance of ~$23 million for FY26 assumes that revenue will begin recovering in the back half of the year as guided. If U.S. sales growth fails to reaccelerate or international ex-China growth proves weaker than expected, revenue could come in below the $90–$92 million range, leading to higher-than-anticipated cash burn due to operating leverage working in reverse. The company did not specify what revenue threshold would trigger covenant concerns under the new credit facility or how it would respond if milestone-based undrawn funds become inaccessible. Additionally, while gross margin improved to 78% in Q1, management guided to a full-year rate of ~75%, noting it will trend lower in the second half due to a higher mix of distributor sales—suggesting that the margin improvement may not be sustainable if international sales shift back toward lower-margin channels. The company also continues to invest in R&D ($4.9M in Q1) and sales expansion, but if these investments are not yielding proportional returns, the operating model could remain structurally unprofitable. With an accumulated deficit and no history of annual profitability, the market may be underestimating how much revenue growth is needed not just to slow cash burn, but to achieve sustainable profitability—especially if macroeconomic pressures or reimbursement headwinds emerge in key markets.

The company’s U.S. sales recovery remains overly dependent on the ramp-up of newly hired sales representatives, introducing execution risk if productivity gains do not materialize on management’s anticipated timeline. While Pulmonx has substantially filled its U.S. field sales roles and leadership positions, it acknowledges that new hires typically take 6 to 9 months to reach full productivity, implying that meaningful contribution from these reps may not begin until mid-to-late 2026. The company’s guidance for sequential improvement and back-half growth acceleration hinges on this ramp, yet it offered no concrete leading indicators—such as quota attainment, activity levels, or conversion rates—to validate that the sales force is progressing beyond mere headcount completion. Historical patterns show that even with full hiring, sales force effectiveness can lag due to insufficient training, unclear territory alignment, or weak adoption of the new near-to-far strategy. Management cited improved culture and stabilized turnover but did not address whether reps are consistently executing the prioritized activities—like setting up high-quality valve programs or securing administrative support—or if they are reverting to diffuse, low-yield efforts. Without evidence of changing behavior or early productivity metrics, the assumption that growth will reaccelerate in the second half relies on hope rather than proven operational readiness, leaving the U.S. recovery vulnerable to delays if reps fail to ramp as expected.
The international growth ex-China, while appearing strong, may be overstated due to reliance on low-base growth and temporary tailwinds that are not sustainable or scalable. Although Pulmonx reported 22% year-over-year international growth excluding China in Q1 FY26, this figure comes off a depressed base from the prior year, particularly in certain direct markets where performance may have been artificially suppressed by one-time factors such as delayed orders, temporary purchasing patterns, or non-recurring tenders. The company did not provide a breakdown of which specific countries or regions are driving this growth, nor did it clarify whether the increase is broad-based or concentrated in a few smaller markets. Furthermore, the 9% constant currency growth suggests that foreign exchange is flattering the reported number, implying that underlying volume growth is even weaker than the headline figure implies. There was no discussion of market share gains, new account acquisition rates outside of the U.S., or repeat purchasing behavior—key indicators of durable demand. Without evidence that this growth is driven by expanding penetration, improved reimbursement, or structural adoption of Zephyr Valves in core European markets, the ex-China performance could reflect a short-term bounce rather than a sustainable trend. If this growth proves transient, the international segment may not deliver the expected inflection in the back half of the year, especially once China-related comparisons lap and the true underlying momentum is tested.
The AeriSeal program, while positioned as a long-term TAM expander, faces significant clinical, regulatory, and commercialization risks that are being underplayed in management’s optimistic timeline for trial completion and potential approval. Management expressed confidence in completing enrollment of the CONVERT II pivotal trial by 2027, yet provided no interim milestones, data monitoring plans, or clarification on the trial’s primary endpoint, statistical power, or patient population specifics—raising questions about whether the timeline is realistic given historical delays in pulmonary device trials. Even if enrollment completes on schedule, the path to regulatory approval remains uncertain, as AeriSeal is a polymer-based sealant delivered via bronchoscopy, a delivery method with mixed historical success in lung applications and potential concerns about long-term safety, durability, and potential for adverse events like migration or inflammation. The company did not address how it plans to differentiate AeriSeal from prior failed sealant technologies or what reimbursement pathway it expects, particularly given that current COPD treatments face stringent cost-effectiveness scrutiny. Furthermore, there was no discussion of commercial readiness—such as training requirements, procedure reimbursement codes, or hospital adoption barriers—suggesting that the assumption of AeriSeal as a near-to-medium term revenue driver may be premature. If clinical outcomes are equivocal or approval is delayed beyond 2027, the expected 20% TAM expansion may not materialize, leaving the company overly reliant on the niche Zephyr Valves market for growth.
The company’s financial leverage and cash runway improvements, while beneficial, may be insufficient to withstand a prolonged delay in revenue recovery, especially if cost-cutting begins to impair growth investments. Although Pulmonx has reduced operating expenses by over 10% through restructuring and secured a $60 million credit facility with additional undrawn capacity, its cash burn guidance of ~$23 million for FY26 assumes that revenue will begin recovering in the back half of the year as guided. If U.S. sales growth fails to reaccelerate or international ex-China growth proves weaker than expected, revenue could come in below the $90–$92 million range, leading to higher-than-anticipated cash burn due to operating leverage working in reverse. The company did not specify what revenue threshold would trigger covenant concerns under the new credit facility or how it would respond if milestone-based undrawn funds become inaccessible. Additionally, while gross margin improved to 78% in Q1, management guided to a full-year rate of ~75%, noting it will trend lower in the second half due to a higher mix of distributor sales—suggesting that the margin improvement may not be sustainable if international sales shift back toward lower-margin channels. The company also continues to invest in R&D ($4.9M in Q1) and sales expansion, but if these investments are not yielding proportional returns, the operating model could remain structurally unprofitable. With an accumulated deficit and no history of annual profitability, the market may be underestimating how much revenue growth is needed not just to slow cash burn, but to achieve sustainable profitability—especially if macroeconomic pressures or reimbursement headwinds emerge in key markets.

Geographical Breakdown of Revenue (2024)

History

Peer group

Peer Comparison

Companies in the Medical Devices

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	265.71 Bn	37.57	5.61	41.37 Bn
2	ABT	Abbott Laboratories	189.37 Bn	40.28	3.93	31.16 Bn
3	DHR	Danaher Corp /De/	164.78 Bn	38.05	6.43	26.48 Bn
4	ISRG	Intuitive Surgical Inc	157.85 Bn	53.38	13.63	-
5	MDT	Medtronic plc	129.66 Bn	24.79	3.45	28.15 Bn
6	SYK	Stryker Corp	121.82 Bn	33.62	4.63	14.93 Bn
7	BSX	Boston Scientific Corp	63.42 Bn	18.11	3.01	11.95 Bn
8	LUNG	Pulmonx Corp	0.12 Bn	-	-	0.04 Bn

Pulmonx LUNG

About

Investment Thesis

Geographical Breakdown of Revenue (2024)

Peer Comparison

Create an account

Sign In

Reset Password